AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis

 AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis

AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis

Shots:

  • The CHMP positive opinion is based on P-III SELECT program including SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY assessing Rinvoq in 4,400+ patients with mod. to sev. active RA
  • In P-III studies, Rinvoq improved signs and symptoms of RA, inhibited radiographic progression and improved physical function, both as a monothx. and in combination with conventional synthetic DMARDs
  • Rinvoq is a selective and reversible JAK inhibitor, currently under review with health authorities globally to treat mod. to sev. active RA and being evaluated in P-III studies for multiple immune-mediated inflammatory diseases

Click here to­ read full press release/ article | Ref: AbbVie | Image: Supply Chain Asia

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post